ARWR
Arrowhead Pharmaceuticals, Inc.NASDAQHealthcare$61.03-3.00%ClosedMarket Cap: $8.55B
As of 2026-04-06
Valuation
P/E (TTM)
42.25
PEG
0.32
P/B
15.06
P/S
7.84
EV/EBITDA
23.42
DCF Value
$-101.64
FCF Yield
3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.7%
Operating Margin
27.6%
Net Margin
18.5%
ROE
36.1%
ROA
12.6%
ROIC
20.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $264.0M | 100.0% | $40.8M | $30.8M | $0.22 | — |
| Q4 2025 | $256.5M | 100.0% | $44.1M | $-23.8M | $-0.17 | — |
| FY 2025 | $829.4M | 97.1% | $98.3M | $-1.6M | $-0.01 | — |
| Q3 2025 | $27.8M | 77.6% | $-165.6M | $-175.2M | $-1.26 | — |
| Q2 2025 | $542.7M | 100.0% | $381.2M | $370.4M | $2.75 | — |
| Q1 2025 | $2.5M | 100.0% | $-161.4M | $-173.1M | $-1.39 | — |
| Q4 2024 | $23.6M | 42.5% | $-162.2M | $-170.5M | $-1.40 | — |
| FY 2024 | $3.6M | 100.0% | $-601.1M | $-599.5M | $-5.00 | — |
| Q3 2024 | $0.00 | -Infinity% | $-176.1M | $-170.8M | $-1.38 | — |
| Q2 2024 | $0.00 | -Infinity% | $-126.2M | $-125.3M | $-1.02 | — |
| Q1 2024 | $3.6M | 100.0% | $-136.5M | $-132.9M | $-1.24 | — |
| Q4 2023 | $16.1M | 76.0% | $-108.3M | $-109.7M | $-1.02 | — |